A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers

Journal of Medicinal Chemistry

Volumn 46, Issue 16, 2003, Pages 3514-3525

  Fray, M Jonathan ^a   Dickinson, Roger P ^a   Huggins, John P ^a   Occleston, Nicholas L ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Renovo   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[[2,2 DIMETHYL 1 [[(2 METHOXY 1 PHENYLETHYL)AMINO]CARBONYL]PROPYL]AMINO]CARBONYL] 6 (3 METHYL 4 PHENYLPHENYL)HEXANOIC ACID; COLLAGENASE 3; FIBRONECTIN; GELATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; UK 370106; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CHRONIC DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; EPITHELIZATION; KERATINOCYTE; NONHUMAN; PROTEIN DEGRADATION; RABBIT; RAT; SKIN ULCER; TREATMENT OUTCOME; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CHRONIC DISEASE; FIBRONECTINS; GELATIN; HEXANOIC ACIDS; HUMANS; KERATINOCYTES; MALE; MATRIX METALLOPROTEINASE 3; PROTEASE INHIBITORS; RABBITS; SKIN; SKIN DISEASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; ULCER; VALINE;

EID: 0041842667     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0308038     Document Type: Article

References (65)

1. Martin, P., Wound healing - aiming for perfect skin regeneration. Science 1997, 276, 75-81.
2. Falanga, V. Chronic wounds - pathophysiologic and experimental considerations. J. Invest. Dermatol. 1993, 134, 721-725.
3. Ruckley, C. V.; Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997, 48, 67-69.
4. Mayberry, J. C.; Moneta, G. L.; Taylor, L. M.; Porter, J. M. 15-year results of ambulatory compression therapy for chronic venous ulcers. Surgery 1991, 109, 575-581.
5. Tarnuzzer, R. W.; Macauley, S. P.; Mast, B. A.; Gibson, J. S.; Stacey, M. C.; Trengrove, N.; Moldawer, L. L.; Burslem, F.; Schultz, G. S. Epidermal growth factor in wound healing: a model for the molecular pathogenesis of chronic wounds. Growth factors and wound healing; Springer-Verlag: New York, 1997; Chapter 12, pp 206-228.
6. Saarialho-Kere, U. K. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch. Dermatol. Res. 1998, 290, Suppl: S47-54.
7. Tarnuzzer, R. W.; Schultz, G. S. Biochemical analysis of acute and chronic wound environments. Wound Rep. Regul. 1996, 4, 321-325.
8. Bucalo, B.; Englstein, W. H.; Falanga, V. Inhibition of cell proliferation by chronic wound fluid. Wound Rep. Regul. 1993, 1, 181-186.
9. Herrick, S. E.; Ireland, G. W.; Simon, D.; McCollum, C. N.; Ferguson, M. W. J. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J. Invest. Dermatol. 1996, 106, 187-193.
10. Grinnell, F.; Ho, C. H.; Wysocki, A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J. Invest. Dermatol. 1992, 98, 410-416.
11. Alper, J. C.; Tibbetts, L. L.; Sarazen, A. A. J. The in vitro response of fibroblasts to the fluid that accumulates under a vapour-permeable membrane. J. Invest. Dermatol. 1985, 84, 513-515.
12. Wilhelm, S. M.; Collier, I. E.; Kronberger, A.; Elsen, A. Z.; Barry, L.; Gregory, A.; Bauer, E. A.; Goldberg, G. I. Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc. Nat. Acad. Sci. U.S.A. 1987, 84, 6725-6729.
13. Mast, B. A.; Schultz, G. S. Interactions of cytokines, growth factors and proteases in acute and chronic wounds. Wound Rep. Regul. 1996, 4, 411-420.
14. Saarialho-Kere, U. K.; Pentland, A. P.; Birkedal-Hansen, H.; Parks, W. C.; Welgus, H. G.; Distinct populations of basal keratinocytes express stromolysis-1 and stromolysis-2 in chronic wounds, J. Clin. Invest. 1994, 94, 79-87.
15. Vaalamo, M.; Weckroth, M.; Puolakkainen, P.; Kere, J.; Saarinen, P.; Lauharanta, J.; Saarialho-Kere, U. K.; Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br. J. Dermatol. 1996, 135, 52-59.
16. Weckroth, M.; Vaheri, A.; Lauharanta, J.; Sorsa, T.; Konttinen, Y. T. Matrix metalloproteases, gelatinase and collagenase, in chronic dermal ulcers. J. Invest. Dermatol. 1996, 106, 1119-1124.
17. Wysocki, A. B.; Stainocoico, L.; Grinnel, F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteases MMP-2 and MMP-9. J. Invest. Dermatol, 1993, 101, 64-68.
18. Mast, A. E.; Enghild, J. J.; Nagase, H.; Suzuki, K.; Pizzo, S. V.; Salvesen, G. Kinetics and physiological relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72kDa gelatinase/type IV collagenase), and -3 (stromelysin). J. Biol. Chem. 1991, 266, 15810-15816.
19. Rao, C. N.; Ladin, D. A.; Liu, Y. Y.; Chilukuri, K.; Hou, Z. Z.; Woodley, D. T. α1-antitrypsin is degraded and nonfunctional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J. Invest. Dermatol. 1995, 105, 572-578.
20. Hoffman, R.; Noble, J.; Eagle, M. The use of proteases as prognostic markers for the healing of venous leg ulcers. J. Wound Care 1999, 8, 273-276.
21. Pei, D.; Majmundar, G.; Weiss, S. J. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 1994, 269, 25849.
22. Bullard, K. M.; Lund, L.; Mudgett, J. S.; Mellin, T. N.; Hunt, T. K.; Murphy, B.; Ronan, J.; Werb, Z.; Banda, M. J. Impaired Wound Contraction in Stromelysin-1-Deficient Mice. Ann. Surgery 1999, 230, 260-5.
23. For recent reviews, see Wojtowicz-Praga, S.; Clinical potential of matrix metalloprotease inhibitors. Drugs R&D 1999, 1, 117-129. De, B.; Natchus, M. G.; Cheng, M.; Pikul, S.; Almstead, N. G.; Taiwo, Y. O.; Snider, C. E.; Chen, L.; Barnett, B.; Gu, F.; Dowty, M. The next generation of MMP inhibitors: design and synthesis. Ann. N. Y. Acad. Sci. 1999, 878 (Inhibition of Matrix Metalloproteinases), 40-60. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Applications of Matrix Metalloprotease Inhibitors. Chem. Rev. 1999, 99, 2735-2776. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteases Curr. Opin. Chem. Biol. 1998, 2, 466. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359.
24. For recent reviews, see Wojtowicz-Praga, S.; Clinical potential of matrix metalloprotease inhibitors. Drugs R&D 1999, 1, 117-129. De, B.; Natchus, M. G.; Cheng, M.; Pikul, S.; Almstead, N. G.; Taiwo, Y. O.; Snider, C. E.; Chen, L.; Barnett, B.; Gu, F.; Dowty, M. The next generation of MMP inhibitors: design and synthesis. Ann. N. Y. Acad. Sci. 1999, 878 (Inhibition of Matrix Metalloproteinases), 40-60. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Applications of Matrix Metalloprotease Inhibitors. Chem. Rev. 1999, 99, 2735-2776. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteases Curr. Opin. Chem. Biol. 1998, 2, 466. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359.
25. For recent reviews, see Wojtowicz-Praga, S.; Clinical potential of matrix metalloprotease inhibitors. Drugs R&D 1999, 1, 117-129. De, B.; Natchus, M. G.; Cheng, M.; Pikul, S.; Almstead, N. G.; Taiwo, Y. O.; Snider, C. E.; Chen, L.; Barnett, B.; Gu, F.; Dowty, M. The next generation of MMP inhibitors: design and synthesis. Ann. N. Y. Acad. Sci. 1999, 878 (Inhibition of Matrix Metalloproteinases), 40-60. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Applications of Matrix Metalloprotease Inhibitors. Chem. Rev. 1999, 99, 2735-2776. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteases Curr. Opin. Chem. Biol. 1998, 2, 466. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359.
26. For recent reviews, see Wojtowicz-Praga, S.; Clinical potential of matrix metalloprotease inhibitors. Drugs R&D 1999, 1, 117-129. De, B.; Natchus, M. G.; Cheng, M.; Pikul, S.; Almstead, N. G.; Taiwo, Y. O.; Snider, C. E.; Chen, L.; Barnett, B.; Gu, F.; Dowty, M. The next generation of MMP inhibitors: design and synthesis. Ann. N. Y. Acad. Sci. 1999, 878 (Inhibition of Matrix Metalloproteinases), 40-60. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Applications of Matrix Metalloprotease Inhibitors. Chem. Rev. 1999, 99, 2735-2776. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteases Curr. Opin. Chem. Biol. 1998, 2, 466. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359.
27. For recent reviews, see Wojtowicz-Praga, S.; Clinical potential of matrix metalloprotease inhibitors. Drugs R&D 1999, 1, 117-129. De, B.; Natchus, M. G.; Cheng, M.; Pikul, S.; Almstead, N. G.; Taiwo, Y. O.; Snider, C. E.; Chen, L.; Barnett, B.; Gu, F.; Dowty, M. The next generation of MMP inhibitors: design and synthesis. Ann. N. Y. Acad. Sci. 1999, 878 (Inhibition of Matrix Metalloproteinases), 40-60. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Applications of Matrix Metalloprotease Inhibitors. Chem. Rev. 1999, 99, 2735-2776. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteases Curr. Opin. Chem. Biol. 1998, 2, 466. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359.
28. Saarialho-Kere, U. K.; Kovacs, S. O.; Pentland, A. P. Cell-matrix interaction modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J. Clin. Invest. 1993, 92, 2858-66.
29. Pilcher, B. K.; Dumin, J. A.; Sudbeck, B. D.; Krane, S. M.; Welgus, H. G.; Parks, W. C. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J. Cell Biol. 1997, 137, 1445-57.
30. Agren, M. S. Gelatinase activity during wound healing. Brit. J. Dermatology 1994, 131, 634-40.
31. Salo, T.; Mäkänen, M.; Kylmäniemi, M.; Autio-Harmainen, H.; Larjava, H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab. Invest. 1994, 70, 176-82.
32. Taraboletti, G.; Garofalo, A.; Belotti, D.; Drudis, T.; Borsotti, P.; Scanziani, E.; Brown, P. D.; Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 1995, 87, 293-8.
33. Cook, H.; Stephens, P.; Davies, K. J.; Harding, K. G.; Thomas, D. W. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2 and MMP-2 activity. J. Invest. Dermatol. 2000, 115, 225-233.
34. Wall, S.; Murphy, G.; Matrix metalloproteinase expression in impaired wound healing. Int. J. Exp. Pathol. 2000, 81, A27.
35. Takino, T.; Sato, H.; Shinagawa, A.; Seiki, M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 1995, 270, 23013-20.
36. Vaalamo, M.; Mattila, L.; Johansson, N.; Kariniemi, A. L.; Karjalainen-Lindsberg, M. L.; Kahari, V. M.; Saarialho-Kere U. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J. Invest. Dermatol. 1997, 109, 96-101.
37. Scott, K. A.; Wood, E. J.; Karran, E. H. A Matrix Metalloprotease Inhibitor which prevents Fibroblast-mediated Collagen Lattice Contraction. FEBS Lett. 1998, 441, 137-140.
38. Pilcher, B. K.; Wang, M.; Qin, X.-J.; Parks, W. C.; Senior, R. M.; Welgus, H. G. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann. N. Y. Acad. Sci. 1999, 878, 12-24.
39. Mirastschijski, U.; Impola, U.; Karsdal M. A.; Saarialho-Kere, U.; Agren, M. S. Matrix metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo. J. Invest. Dermatol. 2002, 118, 55-64.
40. Agren, M. S. Matrix metalloproteinases (MMPs) are required for re-epithelialization of cutaneous wounds. Arch. Dermatol. Res. 1999, 291, 583-590.
41. Agren M. S.; Mirastschijski U.; Karlsmark T.; Saarialho-Kere U. K.; Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp. Dermatol. 2001, 10, 337-48.
42. Stocker, W.; Grams, F.; Baumann, U.; Reinmer, P.; Gomis-Ruth, F.; McKay, D.; Bode, W.; The Metzincins - Topological and Sequential Relations between the Astacins, Adamalysins, Serralysins, and Matrixins (Collagenases) Define a Superfamily of Zinc-Peptidases. Protein Sci. 1995, 4, 823-840.
43. Kessler, E.; Takahara, T.; Biniamov, L.; Brusel, M.; Greenspan, D. S. Bone Morphogenetic Protein-1: The Type-1 Procollagen C-Proteinase. Science 1996, 271, 360-362.
44. Fray, M. J.; Burslem, M. F.; Dickinson, R. P. Selectivity of Inhibition of Matrix Metalloproteases MMP-3 and MMP-2 by Succinyl Hydroxamates and their Carboxylic Acid Analogues is Dependent on P3′ Group Chirality. Bioorg. Med. Chem. Lett. 2001, 11, 567-570.
45. Fray, M. J.; Dickinson, R. P. Discovery of Potent and Selective Succinyl Hydroxamate Inhibitors of Matrix Metalloprotease-3 (Stromelysin-1). Bioorg. Med. Chem. Lett. 2001, 11, 571-574.
46. Bird, J.; Montana, J. G.; Wills, R. E.; Baxter, A. D.; Owen, D. A. World Patent Appl., 1998, WO 98/39024; Chem. Abstr. 129, 225751.
47. Plattner, J. J.; Marcotte, P. A.; Kleinert, H. D.; Stein, H. H.; Greer, J.; Bolis, G.; Fung, A. K. L.; Bopp, B. A.; Luly, J. R.; Sharn, H. L.; Kempf, D. J.; Rosenberg, S. H.; Dellaria, J. F.; Merits, I.; Perun, T. J. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability. J. Med. Chem. 1988, 31, 2277-88.
48. Evans, D. A.; Wu, L. D.; Wiener, J. J. M.; Johnson, J. S.; Ripin, D. H. B.; Tedrow, J. S. A general method for the synthesis of enantiomerically pure β-substituted, β-amino acids through α-substituted succinic acid derivatives. J. Org. Chem. 1999, 64, 6411-6417.
49. Gomberg, M.; Pernert, J. C. Methylbiphenyls. J. Am. Chem. Soc. 1926, 48, 1372-1384.
50. Pattenden, G.; Teague, S. J. Transannular cyclization as a strategem in synthesis. Total synthesis of (±)-pentalenene. Tetrahedron 1987, 43, 5637-5652.
51. Savino, T. G.; Kanakarajan, K.; Platz, M. S. Unusual temperature-dependent isotope effects in the reactions of phenylcarbene with cyclohexene and cyclohexane. J. Org. Chem. 1986, 51, 1305-1309.
52. Smith, A. B., III; Yager, K. M.; Taylor, C. M. Enantioselective synthesis of diverse α-amino phosphonate diesters. J. Am. Chem. Soc. 1995, 117, 10879-10888.
53. Pospisek, J.; Blaha, K. Amino acids and peptides. CXXXIX. tert-Leucine and its simple peptides. Collect. Czech. Chem. Commun. 1977, 42, 1069-1076.
54. Makela, M.; Larjava, H.; Pirila, E.; Maisi, P.; Salo, T.; Sorsa, T.; Uitto, V. J. Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp. Cell Res. 1999, 251, 67-78.
55. McCawley, L. J.; O'Brien, P.; Hudson, L. G. Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/ HGF)-mediated keratinocyte migration is co-incident with induction of matrix metalloproteinase (MMP)-9. J. Cell. Physiol. 1998, 176, 255-265.
56. Esser, C. K.; Bugianesi, R. L.; Caldwell, C. G.; Chapman, K. T.; Durette, P. L.; Giotra, N. N.; Kopka, I. E.; Lanza, T. J.; Levorse, D. A.; MacCoss, M.; Owens, K. A.; Ponpipom, M. M.; Simeone, J. P.; Harrison, R. K.; Niedzwiecki, L.; Becker, J. W.; Marcy, A. I.; Axel, M. G.; Christen, A. J.; McDonnell, J.; Moore, V. L.; Olszewski, J. M.; Saphos, C.; Visco, D. M.; Shen, F.; Colletti, A.; Krieter, P. A.; Hagmann, W. K. Inhibition of stromelysin-1 (MMP-3) by P1′-biphenylethyl carboxyalkyl dipeptides. J. Med. Chem. 1997, 40, 1026.
57. Chapman, K. T.; Durette, P. L.; Caldwell, C. G.; Sperow, K. M.; Niedzwiecki, L.; Harrison, R. K.; Saphos, C.; Christen, A. J.; Olszewski, J. M.; Moore, V. L.; MacCoss, M.; Hagmann, W. K. Orally active inhibitors of stromelysin-1 (MMP-3). Bioorg. Med. Chem. Lett. 1996, 6, 803.
58. Bender, S. Presentation at The Second Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, Jan 26-31, 1997.
59. Davidson, Prof. J. M. unpublished work. A delayed healing wound model in the rat has also been described; see Chen, C.; Schultz, G. S.; Bloch, M.; Edwards, P. D.; Tebes, S.; Mast, B. A. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Rep. Regul. 1999, 7, 486-494, and a model of wound healing in diabetic pigs, see M. C. Niciporciukas, World Patent WO 98/57169, 1998.
60. Davidson, Prof. J. M. unpublished work. A delayed healing wound model in the rat has also been described; see Chen, C.; Schultz, G. S.; Bloch, M.; Edwards, P. D.; Tebes, S.; Mast, B. A. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Rep. Regul. 1999, 7, 486-494, and a model of wound healing in diabetic pigs, see M. C. Niciporciukas, World Patent WO 98/57169, 1998.
61. Beekman, B.; van El, B.; Drijfhout, J. W.; Ronday, H. K.; TeKoppele, J. M. Highly increased levels of active stromelysin in rheumatoid synovial fluid determined by a selective fluorogenic assay. 1997, FEBS Lett. 418, 305-309.
62. Knight, C. G.; Wilenbrock, F.; Murphy, G.; A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
63. Bickett, D. M.; Green, M. D.; Berman, J.; Dezube, M. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal. Biochem. 1993, 212, 58-64.
64. Nagase, H.; Fields, C. G.; Fields, G. B. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin-1 (matrix metalloproteinase -3). J. Biol. Chem. 1994, 269, 20952-20957.
65. Will, H.; Atkinson, S. J.; Butler, G. S.; Smith, B.; Murphy, G. The soluble catalytic domain of membrane type-1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates auto proteolytic activation. Regulation by TIMP 2 and TIMP 3. J. Biol. Chem. 1996, 271, 17119-17123.